Back to All Collaborations

Celgene MMV Partnership

Active Since: 2012

Contributing to SDGs…

Identifying new therapies to treat blood and liver-stage malaria.

MEMBER COMPANIES

PARTNER ORGANISATIONS

  • Product development partnerships

    Medicines for Malaria Venture (MMV)

Objectives

  • This project aims to identify new therapies to treat blood and liver-stage malaria.

What are the health needs and challenges?

The worldwide disease burden for malaria is enormous, with more than half of the world at risk and with the development of resistance to existing therapies.

Partnership activities and how they address needs and challenges

In collaboration with Medicines for Malaria Venture (MMV), Celgene has developed numerous new classes of anti-malarial treatments from a screening against the major pathogen, Plasmodium falciparum. Currently, the work is focused on identifying a single treatment that could be tested against various strains of malaria.

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs

SDG 9: Industry Innovation and Infrastructure

SDG 17: Partnerships for the Goals 

ADDITIONAL INFORMATION

EXTERNAL RESEARCH